News articles about Pacira Pharmaceuticals (NASDAQ:PCRX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pacira Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.2857276555282 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) to Announce $0.12 Earnings Per Share (americanbankingnews.com)
- Pacira Pharmaceuticals Sees RS Rating Climb To 75 (finance.yahoo.com)
- Pacira Pharmaceuticals names Scott Braunstein COO, Richard Scranton as chief scientific officer – MarketWatch (marketwatch.com)
- Pacira Pharma (PCRX) Names Scott Braunstein as COO and Richard Scranton as Chief Scientific Officer – StreetInsider.com (streetinsider.com)
A number of research firms have recently issued reports on PCRX. Jefferies Group reaffirmed a “buy” rating and set a $59.00 price objective on shares of Pacira Pharmaceuticals in a report on Thursday, September 7th. Mizuho reaffirmed a “buy” rating and set a $53.00 price objective (down from $54.00) on shares of Pacira Pharmaceuticals in a report on Tuesday, August 22nd. Needham & Company LLC began coverage on shares of Pacira Pharmaceuticals in a report on Tuesday, August 22nd. They set a “buy” rating and a $55.00 price objective for the company. Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Tuesday, October 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $52.00 price objective on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $48.86.
Pacira Pharmaceuticals (PCRX) opened at $44.80 on Monday. Pacira Pharmaceuticals has a 52-week low of $29.81 and a 52-week high of $58.95. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $68.99 million. During the same quarter last year, the company earned $0.20 EPS. The firm’s revenue was down 1.6% compared to the same quarter last year. analysts expect that Pacira Pharmaceuticals will post -0.85 EPS for the current year.
In other Pacira Pharmaceuticals news, SVP James B. Jones sold 850 shares of the business’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $41.11, for a total value of $34,943.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mark A. Kronenfeld acquired 1,000 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was purchased at an average price of $41.60 per share, for a total transaction of $41,600.00. Following the transaction, the director now directly owns 6,795 shares of the company’s stock, valued at approximately $282,672. The disclosure for this purchase can be found here. Insiders sold 69,735 shares of company stock worth $2,692,594 in the last 90 days. Corporate insiders own 6.60% of the company’s stock.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.